Serum protein fingerprinting

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 6, 2003, Pages 584-593

  Veenstra, Timothy D ^a   Conrads, Thomas P ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Biomarkers; Cancer; Early diagnosis; Mass spectrometry; Proteomic patterns; Serum fingerprinting

Indexed keywords

BIOLOGICAL MARKER; ONCOPROTEIN; PLASMA PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOTECHNOLOGY; BLOOD ANALYSIS; BODY FLUID; BREAST CANCER; CANCER SCREENING; COMPUTER PROGRAM; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; ISOELECTRIC FOCUSING; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHODOLOGY; OVARY CANCER; PATTERN RECOGNITION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TWO DIMENSIONAL ELECTROPHORESIS;

BLOOD PROTEINS; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; PEPTIDE MAPPING; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 0347719622     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Hochstrasser DF, Williams KL: Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev (1996) 13:19-50.
2. Phizicky E, Bastiaens PI, Zhu H, Snyder M, Fields S: Protein analysis on a proteomic scale. Nature (2003) 422(6928):208-215.
3. Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature (2003) 422(6928):198-207.
4. Patterson SD, Aebersold RH: Proteomics: The first decade and beyond. Nat Genet (2003) 33(Suppl):311-323.
5. Schieltz DM, Yates JR 3rd: Direct identification of proteins in ultracomplex mixtures. Applications to proteome analysis. Methods Mol Biol (2003) 211:235-245.
6. Resing KA: Analysis of signaling pathways using functional proteomics. Ann NY Acad Sci (2002) 971:608-614.
7. Conrads TP, Issaq HJ, Hoang VM: Current strategies for quantitative proteomics. Adv Protein Chem (2003) 65:133-159.
8. Hanash S: Disease proteomics. Nature (2003) 422(6928):226-232.
9. Temple RJ: A regulatory authority's opinion about surrogate endpoints. In: Clinical Measurement in Drug Evaluation. Nimmo, WS, Tucker GT (Eds), John Wiley & Sons Ltd, Chichester, UK (1995).
10. Rippey JH: Pregnancy tests: Evaluation of current status. Crit Rev Clin Lab Sci (1984) 19(4):353-359.
11. Srivastava S, Gopal-Srivastava R: Biomarkers in cancer screening: A public health perspective. J Nutr (2002) 132(8 Suppl):2471S-2475S.
12. Guppy AE, Rustin GJ: CA 125 response: Can it replace the traditional response criteria in ovarian cancer? Oncologist (2002) 7(5):437-443.
13. Grossklaus DJ, Smith JA, Shappell SB, Coffey CS, Chang SS, Cookson MS: The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. Urol Oncol (2002) 7(5):195-198.
14. Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, Springer DL, Pounds JG: Toward a human blood serum proteome: Analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics (2002) 1(12):947-955.
15. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD: Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics (2003) 2(10):1096-1103.
16. Pieper R, Su Q, Gatlin CL, Huang ST, Anderson NL, Steiner S: Multicomponent immunoaffinity subtraction chromatography: An innovative step towards a comprehensive survey of the human plasma proteome. Proteomics (2003) 3(4):422-432.
17. Hutchens TW, Yip TT: New desorption strategies for the mass-spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom (1993) 7:576-580.
18. Issaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD: SELDITOF MS for diagnostic proteomics. Anal Chem (2003) 75(7):148A-155A.
19. Tanaka K, Hiroaki W, Ido Y, Akita S, Yoshida Y, Yoshida T: Protein and polymer analysis up to m/z 100,000 by laser ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom (1988) 2:151-153.
20. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 359(9306):572-577.
21. Conrads TP, Zhou M, Petricoin EF 3rd, Liotta L, Veenstra TD: Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn (2003) 3(4):411-420.
22. Ozols RF, Rubin SC, Thomas GM, Robboy SJ: Epithelial ovarian cancer. In: Principles and Practice of Gynecological Oncology, 3rd Edition. Hoskins WJ, Perez CA, Young RC (Eds), Lippincott, Williams and Wilkins, Philadelphia, PA, USA (2001):165-182.
23. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC Jr: CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol (1984) 64(5):703-707.
24. Menon U, Jacobs IJ: Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol (2000) 12(1):39-42.
25. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA: Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol (2001) 82(1):40-48.
26. Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence, 3rd Edition. Holland JH (Ed), MIT Press, Cambridge, MA, USA (1994).
27. Kohonen T: The self-organizing map. Proceedings of the IEEE (1990), 78:1464-1480.
28. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res (2002) 62(13):3609-3614.
29. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 94(20):1576-1578.
30. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL Jr: Boosted decision tree analysis of surface-enhanced laser desorptiontio/iozation mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem (2002) 48(10):1835-1843.
31. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem (2002) 48(8):1296-1304.
32. Bast RC Jr: Status of tumor markers in ovarian cancer screening. J Clin Oncol (2003) 21 (10 Suppl):200-205.
33. Anderson NL, Anderson NG: The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics (2002) 1(11):845-867.
34. Xiao Z, Conrads TP, Lucas DA, Janini GM, Schaefer CF, Beutow KH, Issaq HJ, Veenstra TD: Direct ampholyte-free liquid phase isoelectric peptide focusing: Application to the human serum proteome. Electrophoresis (2003): in press.
35. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC: Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res (2003) 9(8):2904-2911.
36. Basso D, Valerio, A, Brigato L, Panozzo, MP, Miola M, Lucca T, Ujka F, Zaninotto M, Avogaro A, Plebani M: An unidentified pancreatic cancer cell product alters some intracellular pathways of glucose metabolism in isolated rat hepatocytes. Pancreas (1997) 15(2):132-138.
37. Rubin RB, Merchant M: A rapid protein profiling system that speeds study of cancer and other diseases. Am Clin Lab (2000) 19(8):28-29.
38. Seftor REB, Seftor EA, Koshikawa N, Meltzer PS, Gardner LMG, Bilban M, Stetler-Stevenson WG, Quaranta V, Hendrix MJC: Cooperative interactions of laminin 5 γ2 chain, matrix metalloproteinase-2, and membrane type-1-matrixt/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res (2001) 61 (17):6322-6327.
39. Diamandis EP: Re: Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2003) 95(6):489-490.